Discovery of highly potent and selective EGFR^T790M/L858R TKIs against NSCLC based on molecular dynamic simulation

Area of Science:

• Medicinal Chemistry
• Oncology
• Molecular Biology

Background:

• Epidermal growth factor receptor (EGFR) is a key target in non-small cell lung cancer (NSCLC) drug development.
• Third-generation EGFR tyrosine kinase inhibitors (TKIs) like Osimertinib are effective but cause side effects due to wild-type EGFR inhibition.
• A need exists for novel inhibitors with high selectivity for mutant EGFR (T790M) over wild-type (EGFR^WT).

Purpose of the Study:

• To design, synthesize, and evaluate novel Osimertinib derivatives as potent and selective EGFR inhibitors.
• To identify compounds with improved efficacy and reduced side effects compared to existing therapies.
• To explore new therapeutic strategies for NSCLC targeting EGFR T790M mutations.

Main Methods:

• Molecular dynamic simulations guided the design of new compounds.
• Synthesis and in vitro evaluation of Osimertinib derivatives for kinase inhibitory activity and selectivity.
• Cell-based assays to assess activity against NSCLC cell lines (NCI-H1975, HCC827) and study mechanisms of action (cell cycle, apoptosis).

Main Results:

• Several potent and selective Osimertinib derivatives were identified, including compounds 7f, 7g, 7k, 7m, and 7n.
• Compound 7m exhibited the highest selectivity for EGFR^T790M/L858R (approximately 2500-fold).
• Compound 7m demonstrated significant activity against NCI-H1975 and HCC827 cells, inducing G2/M cell cycle arrest and apoptosis.

Conclusions:

• Compound 7m is a highly selective and potent inhibitor of EGFR^T790M/L858R.
• 7m shows promise as a potential drug candidate for NSCLC treatment, warranting further pharmacodynamic and pharmacokinetic studies.
• These findings provide valuable insights for developing next-generation EGFR inhibitors with enhanced selectivity and efficacy.